Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
D-Wave Q3 2025 Earnings Call - Demonstrated quantum advantage and expanding commercial traction
D-Wave's Q3 2025 report reveals strong commercial momentum with 100% revenue growth year-over-year, driven by system sales upgrades, quantum computing as a service (QCAS), and professional services. N...
- D-Wave reported Q3 2025 revenue of $3.7 million, doubling year-over-year, with diverse revenue streams from system upgrades, QCAS, and professional services.
- Signed a EUR 10 million, five-year contract with Q Alliance and the Italian government for half-capacity access to an Advantage II system, highlighting global expansion.
- Demonstrated quantum advantage on real-world optimization problems, outperforming classical and competing quantum approaches by up to 1,000x on test cases.
- +12 more takeaways
Galapagos 3Q 2025 Earnings Call - Strategic Wind Down of Self-Therapy Business and Pivot to Business Development
Galapagos' third quarter 2025 earnings call revealed a company at a crossroads, decisively moving away from its self-therapy business after a futile five-month effort to find viable buyers. Despite of...
- Galapagos to wind down its self-therapy business after no viable acquisition offers despite offering minimal upfront consideration and capital support.
- Approximately 365 employees across sites in Belgium, Netherlands, US, China affected; company in consultation with Works Councils, expecting resolution by Q1 2026.
- Company holds approximately €3 billion in cash and investments (~€46 per share), with significant interest income and royalty streams from Jyseleca continuing into the mid-2030s.
- +11 more takeaways
Oscar Health 3Q 2025 Earnings Call - Navigating Higher Morbidity and Positioned for 2026 Profitability
Oscar Health reported a 23% revenue surge to $3 billion in Q3 2025 amid rising market morbidity driven by Medicaid redeterminations and program integrity efforts. Despite a 380 basis point increase in...
- Q3 2025 revenue rose 23% year over year to approximately $3 billion driven by higher membership.
- Medical Loss Ratio increased 380 basis points to 88.5%, reflecting higher market morbidity and program integrity impacts.
- SG&A expense ratio improved by 150 basis points to 17.5%, showcasing disciplined cost management and operating leverage.
- +7 more takeaways
Celsius Holdings Q3 2025 Earnings Call - Strategic Expansion and Integration Drive Market Share Growth and Portfolio Scaling
Celsius Holdings marked a pivotal third quarter in 2025 with transformative moves building on their acquisition of Alani Nu and the addition of Rockstar Energy, further cementing their role as PepsiCo...
- Celsius Holdings expanded its energy portfolio with the acquisition of Rockstar Energy and deeper integration of Alani Nu into PepsiCo’s U.S. distribution network beginning December 1, 2025.
- The company’s total energy portfolio achieved over 20% U.S. energy drink market share in tracked channels, growing 31% year-over-year versus the category’s slower pace.
- Third quarter 2025 revenue surged 173% year-over-year to approximately $725 million, driven by brand portfolio growth and international expansion.
- +7 more takeaways
United Homes Group Q3 2025 Earnings Call - Navigating Uneven Market with September Sales Rebound and Expanding Communities
United Homes Group reported a challenging third quarter in 2025 amidst a sluggish housing market marked by elevated inventory levels and affordability pressures. The company experienced a decline in r...
- United Homes Group's board completed a strategic review and decided to remain an independent public company amid current macroeconomic conditions.
- Several board members plan to resign by November 14, with steps underway to appoint new independent directors to comply with NASDAQ rules.
- Q3 2025 saw uneven demand due to high inventory levels and affordability challenges, negatively impacting industry confidence and sales.
- +7 more takeaways
Lesaka Technologies Q1 FY2026 Earnings Call - Strong Growth and Strategic Integration Across Divisions
Lesaka Technologies reported robust results in Q1 FY2026, hitting the lower end of revenue guidance at ZAR 1.53 billion, up 45% year-on-year, and delivering group adjusted EBITDA of ZAR 271 million, a...
- Lesaka Technologies met its guidance for the 13th consecutive quarter with Q1 FY2026 revenue at ZAR 1.53 billion, up 45% YoY.
- Group adjusted EBITDA reached ZAR 271 million, marking a 61% year-on-year increase, reflecting improved earnings quality with fewer non-recurring items.
- Adjusted earnings doubled to ZAR 1.7 per share from ZAR 0.54, indicating strengthened profitability per share.
- +12 more takeaways
Commerce Third Quarter 2025 Earnings Call - AI Integration and Product Innovation Drive Solid Performance with Focus on Profitable Growth
Commerce, formerly BigCommerce, reported Q3 2025 revenue of $86 million, aligning with guidance, and posted non-GAAP operating income of $8 million, exceeding expectations. The company highlights AI a...
- Q3 2025 revenue reached $86 million, in line with guidance, with non-GAAP operating income of $8 million surpassing expectations.
- Annual revenue run rate approximated $356 million, with 76% from enterprise accounts, average revenue per enterprise account up 7% year-over-year.
- Feedonomics is central to Commerce’s AI strategy, syndicating enriched product data to AI platforms like OpenAI, Google Gemini, and Perplexity.
- +12 more takeaways
Apyx Medical Q3 2025 Earnings Call - Aon Launch Drives Surgical Aesthetics Growth and Updated Revenue Guidance
Apyx Medical's third quarter of 2025 marked a pivotal step in its transformation with the successful launch of the Aon body contouring system, driving a 19% revenue increase in its newly rebranded sur...
- Apyx Medical rebranded its advanced energy segment to surgical aesthetics to better align with its evolving business focus.
- Third quarter 2025 total revenue increased 12% year-over-year to $12.9 million, driven primarily by surgical aesthetics product sales.
- Surgical aesthetics revenue rose 19% to $11.1 million, thanks chiefly to the successful commercial launch of the Aon body contouring system.
- +12 more takeaways
Collegium Pharmaceutical 3Q 2025 Earnings Call - Robust Jornay PM Growth and Durable Pain Portfolio Drive Raised Guidance
Collegium Pharmaceutical delivered a strong third quarter in 2025, with total net revenues reaching a record $209.4 million, up 31% year-over-year, driven by significant growth in Jornay PM and sustai...
- Collegium Pharmaceutical achieved record quarterly net revenues of $209.4 million in Q3 2025, a 31% increase year-over-year.
- Jornay PM net revenues hit $41.8 million with prescriptions growing 20% year-over-year, marking it as the fastest-growing ADHD stimulant.
- Jornay's market share in long-acting branded methylphenidate increased to 23.4%, up 6.3 percentage points from a year ago.
- +10 more takeaways
Lantheus 3Q 2025 Earnings Call - Leadership Transition and Strategic Expansion Fuel Confidence Amid Market Stabilization
Lantheus reported a mixed third quarter with total revenues up slightly, driven by Precision Diagnostic growth, while Radiopharmaceutical Oncology revenues, led by Polarify, declined 7%. The company f...
- CEO Brian Markison will retire at the end of 2025; Mary Anne Heino, former CEO and current Board Chair, will serve as interim CEO to ensure a smooth leadership transition.
- Lantheus narrowed 2025 full-year revenue guidance to $1.49-$1.51 billion and adjusted EPS to $5.50-$5.65, reflecting ongoing execution and market dynamics.
- Polarify sales fell 7% year-over-year to $240.6 million despite a 3.3% volume increase; pricing pressures and 340B resets continue to weigh on revenue.
- +12 more takeaways